For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Phaserx, Inc.

USPTO Granted Patents = 13

CIPO Patents = 15

EPO Patents = 3

Forward Citations = 122

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Patrick S Stayton (12 out of 37 patents)

Allan Sachs Hoffman (12 out of 48 patents)

Paul Hickok Johnson (12 out of 16 patents)

4. Anthony Convertine (9 out of 14 patents)

5. Robert W Overell (9 out of 13 patents)

6. Anna S Gall (8 out of 33 patents)

7. Craig L Duvall (7 out of 18 patents)

8. Charbel Diab (7 out of 12 patents)

9. Priyadarsi De (6 out of 8 patents)

10. Mary Gallagher Prieve (6 out of 18 patents)

11. Danielle Benoit (5 out of 11 patents)

12. Sean D Monahan (3 out of 9 patents)

13. Michael S DeClue (3 out of 6 patents)

14. Amber E E Paschal (3 out of 5 patents)

15. Amber E Paschal (2 out of 5 patents)

13 patents: Sort by Forward Citations

1. 10066043 - ω-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization (2018-09-04),

2. 9867885 - Block copolymers (2018-01-16),

3. 9862792 - Diblock copolymers and polynucleotide complexes thereof for delivery into cells (2018-01-09),

4. 9662403 - Micellic assemblies (2017-05-30),

5. 9593169 - Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization (2017-03-14),

6. 9476063 - Diblock copolymers and polynucleotide complexes thereof for delivery into cells (2016-10-25),

7. 9464300 - Multiblock copolymers (2016-10-11),

8. 9415113 - Targeting monomers and polymers having targeting blocks (2016-08-16),

9. 9339558 - Micellic assemblies (2016-05-17),

10. 9220791 - Bispecific intracellular delivery vehicles (2015-12-29),

11. 9211250 - Heterogeneous polymeric micelles for intracellular delivery (2015-12-15),

12. 9006193 - Polymeric carrier (2015-04-14),

13. 8822213 - Bispecific intracellular delivery vehicles (2014-09-02),

PhaseRx, Inc. is a biopharmaceutical company dedicated to developing new RNA therapeutics to treat patients with life-threatening liver diseases. Their innovative platform technology enables the delivery of RNA specific therapies directly to the liver, addressing the limitations of current treatment options. Through their extensive research and clinical trials, PhaseRx aims to improve the lives of patients and contribute to advancements in the field of RNA therapeutics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

13 Patents

#140 in Seattle, WA

#499 in Washington

#23,099 in US

#43,615 in the World

Seattle, WA, United States of America

Phaserx, Inc.

Forward Citations = 122

50 inventors:

Patrick S Stayton (12 out of 37 patents)

Allan Sachs Hoffman (12 out of 48 patents)

Paul Hickok Johnson (12 out of 16 patents)

4. Anthony Convertine (9 out of 14 patents)

5. Robert W Overell (9 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…